OBJECTIVE: To determine whether indeterminate (Likert-score 3/5) peripheral zone (PZ) multiparametric MRI (mpMRI) studies are classifiable by prostate-specific antigen (PSA), PSA density (PSAD), Prostate Imaging Reporting And Data System version 2 (PI-RADS_v2) rescoring and morphological MRI features. METHODS: Men with maximum Likert-score 3/5 within their PZ were retrospectively selected from 330 patients who prospectively underwent prostate mpMRI (3 T) without an endorectal coil, followed by 20-zone transperineal template prostate mapping biopsies ＋/- focal lesion-targeted biopsy. PSAD was calculated using pre-biopsy PSA and MRI-derived volume. Two readers A and B independently assessed included men with both Likert-assessment and PI-RADS_v2. Both readers then classified mpMRI morphological features in consensus. Men were divided into two groups: significant cancer (≥ Gleason 3 ＋ 4) or insignificant cancer (≤ Gleason 3 ＋ 3)/no cancer. Comparisons between groups were made separately for PSA & PSAD using Mann-Whitney test and morphological descriptors with Fisher's exact test. PI-RADS_v2 and Likert-assessment were descriptively compared and percentage inter-reader agreement calculated. RESULTS: 76 males were eligible for PSA & PSAD analyses, 71 for PI-RADS scoring, and 67 for morphological assessment (excluding significant image artefacts). Unlike PSA (p = 0.915), PSAD was statistically different (p = 0.004) between the significant [median: 0.19 ng ml-2 (interquartile range: 0.13-0.29)] and non-significant/no cancer [median: 0.13 ng ml-2 (interquartile range: 0.10-0.17)] groups. Presence of mpMRI morphological features was not significantly different between groups. Subjective Likert-assessment discriminated patients with significant cancer better than PI-RADS_v2. Inter-reader percentage agreement was 83% for subjective Likert-assessment and 56% for PI-RADS_v2. CONCLUSION: PSAD may categorize presence of significant cancer in patients with Likert-scored 3/5 PZ mpMRI findings. Advances in knowledge: PSAD may be used in indeterminate PZ mpMRI to guide decisions between biopsy vs monitoring.
OBJECTIVE: To determine whether indeterminate (Likert-score 3/5) peripheral zone (PZ) multiparametric MRI (mpMRI) studies are classifiable by prostate-specific antigen (PSA), PSA density (PSAD), Prostate Imaging Reporting And Data System version 2 (PI-RADS_v2) rescoring and morphological MRI features. METHODS:Men with maximum Likert-score 3/5 within their PZ were retrospectively selected from 330 patients who prospectively underwent prostate mpMRI (3 T) without an endorectal coil, followed by 20-zone transperineal template prostate mapping biopsies ＋/- focal lesion-targeted biopsy. PSAD was calculated using pre-biopsy PSA and MRI-derived volume. Two readers A and B independently assessed included men with both Likert-assessment and PI-RADS_v2. Both readers then classified mpMRI morphological features in consensus. Men were divided into two groups: significant cancer (≥ Gleason 3 ＋ 4) or insignificant cancer (≤ Gleason 3 ＋ 3)/no cancer. Comparisons between groups were made separately for PSA & PSAD using Mann-Whitney test and morphological descriptors with Fisher's exact test. PI-RADS_v2 and Likert-assessment were descriptively compared and percentage inter-reader agreement calculated. RESULTS: 76 males were eligible for PSA & PSAD analyses, 71 for PI-RADS scoring, and 67 for morphological assessment (excluding significant image artefacts). Unlike PSA (p = 0.915), PSAD was statistically different (p = 0.004) between the significant [median: 0.19 ng ml-2 (interquartile range: 0.13-0.29)] and non-significant/no cancer [median: 0.13 ng ml-2 (interquartile range: 0.10-0.17)] groups. Presence of mpMRI morphological features was not significantly different between groups. Subjective Likert-assessment discriminated patients with significant cancer better than PI-RADS_v2. Inter-reader percentage agreement was 83% for subjective Likert-assessment and 56% for PI-RADS_v2. CONCLUSION: PSAD may categorize presence of significant cancer in patients with Likert-scored 3/5 PZ mpMRI findings. Advances in knowledge: PSAD may be used in indeterminate PZ mpMRI to guide decisions between biopsy vs monitoring.
Authors: James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh Journal: J Natl Compr Canc Netw Date: 2010-02 Impact factor: 11.908
Authors: Andrew B Rosenkrantz; Xiaosong Meng; Justin M Ream; James S Babb; Fang-Ming Deng; Henry Rusinek; William C Huang; Herbert Lepor; Samir S Taneja Journal: J Magn Reson Imaging Date: 2015-07-01 Impact factor: 4.813
Authors: Florian A Distler; Jan P Radtke; David Bonekamp; Claudia Kesch; Heinz-Peter Schlemmer; Kathrin Wieczorek; Marietta Kirchner; Sascha Pahernik; Markus Hohenfellner; Boris A Hadaschik Journal: J Urol Date: 2017-03-31 Impact factor: 7.450
Authors: Raphaëlle Renard-Penna; Pierre Mozer; François Cornud; Nicolas Barry-Delongchamps; Eric Bruguière; Daniel Portalez; Bernard Malavaud Journal: Radiology Date: 2015-01-19 Impact factor: 11.105
Authors: Berrend G Muller; Joanna H Shih; Sandeep Sankineni; Jamie Marko; Soroush Rais-Bahrami; Arvin Koruthu George; Jean J M C H de la Rosette; Maria J Merino; Bradford J Wood; Peter Pinto; Peter L Choyke; Baris Turkbey Journal: Radiology Date: 2015-06-18 Impact factor: 11.105
Authors: Jeffrey J Tosoian; Eric JohnBull; Bruce J Trock; Patricia Landis; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter Journal: J Urol Date: 2013-04-30 Impact factor: 7.450
Authors: Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton Journal: Lancet Date: 2017-01-20 Impact factor: 79.321
Authors: Nikolaos Dikaios; Jokha Alkalbani; Mohamed Abd-Alazeez; Harbir Singh Sidhu; Alex Kirkham; Hashim U Ahmed; Mark Emberton; Alex Freeman; Steve Halligan; Stuart Taylor; David Atkinson; Shonit Punwani Journal: Eur Radiol Date: 2015-02-14 Impact factor: 5.315
Authors: David Jean Winkel; Hanns-Christian Breit; Bibo Shi; Daniel T Boll; Hans-Helge Seifert; Christian Wetterauer Journal: Quant Imaging Med Surg Date: 2020-04
Authors: William Devine; Francesco Giganti; Edward W Johnston; Harbir S Sidhu; Eleftheria Panagiotaki; Shonit Punwani; Daniel C Alexander; David Atkinson Journal: J Magn Reson Imaging Date: 2018-12-19 Impact factor: 4.813
Authors: Hayley Pye; Saurabh Singh; Joseph M Norris; Lina M Carmona Echeverria; Vasilis Stavrinides; Alistair Grey; Eoin Dinneen; Elly Pilavachi; Joey Clemente; Susan Heavey; Urszula Stopka-Farooqui; Benjamin S Simpson; Elisenda Bonet-Carne; Dominic Patel; Peter Barker; Keith Burling; Nicola Stevens; Tony Ng; Eleftheria Panagiotaki; David Hawkes; Daniel C Alexander; Manuel Rodriguez-Justo; Aiman Haider; Alex Freeman; Alex Kirkham; David Atkinson; Clare Allen; Greg Shaw; Teresita Beeston; Mrishta Brizmohun Appayya; Arash Latifoltojar; Edward W Johnston; Mark Emberton; Caroline M Moore; Hashim U Ahmed; Shonit Punwani; Hayley C Whitaker Journal: Cancers (Basel) Date: 2021-04-20 Impact factor: 6.575
Authors: Tao Peng; JianMing Xiao; Lin Li; BingJie Pu; XiangKe Niu; XiaoHui Zeng; ZongYong Wang; ChaoBang Gao; Ci Li; Lin Chen; Jin Yang Journal: Int J Comput Assist Radiol Surg Date: 2021-10-22 Impact factor: 2.924
Authors: Nikolaos Dikaios; Francesco Giganti; Harbir S Sidhu; Edward W Johnston; Mrishta B Appayya; Lucy Simmons; Alex Freeman; Hashim U Ahmed; David Atkinson; Shonit Punwani Journal: Eur Radiol Date: 2018-11-19 Impact factor: 5.315